Ken Griffin Co Diagnostics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.02 - $1.75 $5,916 - $10,150	5,800 Added 175.76%	9,100 $11,000
Q2 2024 Aug 14, 2024	SELL	$1.01 - $1.7 $19,796 - $33,320	-19,600 Reduced 85.59%	3,300 $4,000
Q1 2024 May 15, 2024	SELL	$1.06 - $1.42 $53,954 - $72,278	-50,900 Reduced 68.97%	22,900 $25,000
Q4 2023 Feb 14, 2024	BUY	$1.0 - $1.5 $30,300 - $45,450	30,300 Added 69.66%	73,800 $98,000
Q3 2023 Nov 14, 2023	BUY	$1.03 - $1.85 $2,884 - $5,180	2,800 Added 6.88%	43,500 $46,000
Q2 2023 Aug 14, 2023	SELL	$1.04 - $1.64 $11,752 - $18,532	-11,300 Reduced 21.73%	40,700 $45,000
Q1 2023 May 15, 2023	SELL	$1.39 - $3.24 $129,964 - $302,940	-93,500 Reduced 64.26%	52,000 $76,000
Q4 2022 Feb 14, 2023	BUY	$2.32 - $3.68 $74,472 - $118,128	32,100 Added 28.31%	145,500 $366,000
Q3 2022 Nov 14, 2022	SELL	$2.87 - $7.01 $69,454 - $169,642	-24,200 Reduced 17.59%	113,400 $364,000

4.28M

48.2K

53.3K

Ticker CODX
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 33,781,000
Market Cap $24.7M
Description
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.